Home > Insider Trading > Filing (0001123292-17-000694)

Filing Details

Accession Number:: 0001123292-17-000694
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-03-16 17:37:06
Reporting Period:: 2017-03-14

Filing Date:: 2017-03-16
Accepted Time:: 2017-03-16 17:37:06
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1588972	Recro Pharma Inc.	REPH	Pharmaceutical Preparations (2834)	261523233

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1602484	Scp Vitalife Partners (Israel) Ii, L.p.	Suite 190 7 Great Valley Parkway Malvern PA 19355		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2017-03-14	5,454	$8.04	760,662	No	4	S	Direct
Common Stock	Disposition	2017-03-15	6,399	$8.01	754,263	No	4	S	Direct
Common Stock	Disposition	2017-03-16	3,170	$7.93	751,093	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2016.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.73 to $8.26, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.91 to $8.05, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.84 to $8.02, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4.